Hazardous Substances Directive: future coverage for medical devices?:
This article was originally published in Clinica
ERA Technology has published a 253-page final report dealing with the issue of whether medtech products should be covered, or continue to be exempted from the Directive on Restriction of Hazardous Substances (RoHS). More details in Clinica next week.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.